Trinity Biotech PLC (NASDAQ:TRIB) is set to issue its quarterly earnings data on Thursday, July 20th. Analysts expect the company to announce earnings of $0.06 per share for the quarter.
Trinity Biotech PLC (NASDAQ:TRIB) last released its quarterly earnings results on Thursday, April 27th. The company reported $0.01 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.03 by $0.02. Trinity Biotech PLC had a negative net margin of 98.39% and a positive return on equity of 5.00%. The firm had revenue of $23.54 million for the quarter, compared to the consensus estimate of $24.24 million. On average, analysts expect Trinity Biotech PLC to post $0.27 EPS for the current fiscal year and $0.43 EPS for the next fiscal year.
Shares of Trinity Biotech PLC (NASDAQ:TRIB) opened at 5.73 on Tuesday. Trinity Biotech PLC has a 52-week low of $5.20 and a 52-week high of $13.68. The company’s 50 day moving average price is $5.70 and its 200 day moving average price is $6.05. The company’s market capitalization is $126.64 million.
TRIB has been the topic of several research analyst reports. Zacks Investment Research cut Trinity Biotech PLC from a “hold” rating to a “sell” rating in a research note on Wednesday, May 3rd. ValuEngine cut Trinity Biotech PLC from a “hold” rating to a “sell” rating in a research report on Friday, June 2nd.
Trinity Biotech PLC Company Profile
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
Receive News & Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related companies with MarketBeat.com's FREE daily email newsletter.